Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21322056 | 0.84 | ADRA2A (0.48) | TNFMAPTL3MBTL1NPSR1ADRA2A | |
| SCHEMBL11974049 | 0.84 | HTR1A (0.49) | TNFADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL2650387 | 0.83 | TNF (0.49) | TNFSLC6A2SLC6A4KCNH2SLC6A3 | |
| SCHEMBL19365951 | 0.82 | TNF (0.40) | TNFMAPTL3MBTL1NPSR1SLC6A2 | |
| SCHEMBL5696557 | 0.82 | TNF (0.43) | TNFADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL14378254 | 0.81 | THRA (0.43) | TNFADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL5412735 | 0.81 | ADRA2A (0.51) | MAPTL3MBTL1NPSR1ADRA2AADRA2B | |
| SCHEMBL10160283 | 0.80 | SLC6A2 (0.48) | TNFSLC6A2SLC6A4KCNH2SLC6A3 | |
| SCHEMBL12016057 | 0.80 | IDO1 (0.44) | TNFSLC6A2SLC6A4KCNH2SLC6A3 | |
| SCHEMBL18649071 | 0.80 | SLC6A2 (0.45) | TNFADRA2AADRA2BADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2939675-B1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| WO-2019027054-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| CN-108140887-A | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | 株式会社艾迪科 | 2018-06-08 | — | — | CN | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| WO-2007145922-A2 | BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | TNF 4842/4885MAPT 3488/4885L3MBTL1 3394/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | TNF 4842/4885MAPT 3488/4885L3MBTL1 3394/4885 |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | TNF 4621/4885MAPT 4246/4885L3MBTL1 31/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | TNF 4570/4885MAPT 4300/4885L3MBTL1 20/4885 |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | TNF 4860/4885MAPT 2193/4885L3MBTL1 3192/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | TNF 4570/4885MAPT 4300/4885L3MBTL1 20/4885 |
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | TNF 3556/4885MAPT 2735/4885L3MBTL1 2652/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | TNF 239/4885MAPT 4397/4885L3MBTL1 3775/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | TNF 4747/4885MAPT 3825/4885L3MBTL1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.